RMI Partners’s investment focus is novel biopharmaceutical products, medical technologies and diagnostic tools that can help extend human life and make it healthier and more productive. We firmly believe in the future of advanced technology and strive to support innovative projects that are success-oriented and provide adequate profits to the investors.
Our main investment criteria:
* Novel breakthrough technology
* Experienced team
* Significant medical problem
* Tangible commercial prospects in the market
13 November 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced that, on Friday, November 10, 2017, during the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting in New Orleans Charles C. Wykoff presented preliminary results from an exploratory clinical trial of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolone acetonide for suprachoroidal administration with and without intravitreally injected EYLEA® (aflibercept) for the treatment of diabetic macular edema.
08 November 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter and nine months ended September 30, 2017 and provided an update on its key development programs.